Efficacy and safety of low dose Valganciclovir for cytomegalovirus prophylaxis in intermediate risk liver transplant recipients

Trial Profile

Efficacy and safety of low dose Valganciclovir for cytomegalovirus prophylaxis in intermediate risk liver transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2018

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2018 Results assessing safety and efficacy of low dose low dose valganciclovir for cytomegalovirus prophylaxis in intermediate risk liver transplant recipients published in the Liver Transplantation
    • 25 Oct 2017 New trial record
    • 08 Oct 2017 Results presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top